ReviewClinical ophthalmology (Auckland, N.Z.)2026
Tubercular Uveitis: Multimodal Imaging, Immunologic Stratification, and a Practical Framework for Diagnosis and Management.
Review in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tubercular uveitis (TBU) remains difficult to diagnose and monitor because microbiologic confirmation is uncommon and clinical phenotypes overlap with other inflammatory chorioretinal disorders. This narrative review integrates evidence from multimodal imaging, immune testing, systemic tuberculosis evaluation, molecular diagnostics, biomarkers, treatment response, and monitoring to support a practical probability-based approach to suspected TBU. A targeted search of PubMed, Embase, Web of Science, the Cochrane Library, and Google Scholar was conducted for English-language literature through May 10, 2026, prioritizing consensus statements, systematic reviews, multicenter studies, and clinically relevant imaging, biomarker, and treatment reports. Enhanced-depth and swept-source optical coherence tomography, optical coherence tomography angiography, fundus autofluorescence, indocyanine green angiography, and ultra-widefield fluorescein angiography provide complementary information on choroidal granulomas, serpiginous-like choroiditis, retinal vasculitis, ischemia, and paradoxical worsening. Tuberculin skin testing and interferon-gamma release assays support tuberculosis attribution but do not prove ocular causality, while polymerase chain reaction and emerging molecular assays increase specificity when positive. Cytokine profiles, type I interferon signatures, complement C1q, and cell-free DNA remain investigational. TBU should be managed as a clinicoradiologic and immunologic probability diagnosis that links phenotype, imaging, tuberculosis exposure evidence, mimic exclusion, antitubercular therapy decisions, anti-inflammatory timing, and longitudinal monitoring to reduce both missed TBU and unnecessary treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.